

Global Dendritic Cell Cancer Vaccine Immunotherapy Market Research Report 2023

<https://marketpublishers.com/r/G5C23C2724E1EN.html>

Date: December 2023

Pages: 87

Price: US\$ 2,900.00 (Single User License)

ID: G5C23C2724E1EN

Abstracts

Dendritic cells (DCs) are one of the major antigen-presenting cells found in lymphoid organs. Main function of the dendritic cells is antigen display and activation of T-cells. Antigen display presents the identity of pathogen to T-cells for their identification and elimination from the body. These cells have proficiency of capturing and processing tumor antigens, which activates expression of lymphocyte co-stimulatory molecules. Consequently, it results in secretion of cytokines to initiate immune response. Over 60 dendritic cell and tumor cell cancer vaccines are currently in clinical / preclinical stages of development; 70% of the pipeline comprises of dendritic cell cancer vaccines.

According to QYResearch's new survey, global Dendritic Cell Cancer Vaccine Immunotherapy market is projected to reach US\$ 1214.8 million in 2029, increasing from US\$ 622 million in 2022, with the CAGR of 10.1% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Dendritic Cell Cancer Vaccine Immunotherapy market research.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high

costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Dendritic Cell Cancer Vaccine Immunotherapy market with multiple angles, which provides sufficient supports to readers' strategy and decision making.

By Company

Lineage Cell Therapeutics

AVAX Technologies

DCPrime

Gradalis

Heat Biologics

ImmunoCellular Therapeutics

Immunicum

MolecuVax

Northwest Biotherapeutics

Pique Therapeutics

Regeneus

Tessa Therapeutics

Vaccinogen

XEME Biopharma

Segment by Type

Provenge

Apceden

CreaVax

Others

Segment by Application

Pediatrics

Adults

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

The Dendritic Cell Cancer Vaccine Immunotherapy report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)

Chapter 2: Global market size, regional market size. Market Opportunities and Challenges

Chapter 3: Companies' Competition Patterns

Chapter 4: Product Type Analysis

Chapter 5: Product Application Analysis

Chapter 6 to 10: Country Level Value Analysis

Chapter 11: Companies' Outline

Chapter 12: Market Conclusions

Chapter 13: Research Methodology and Data Source

Contents

1 REPORT OVERVIEW

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Provenge

1.2.3 Apceden

1.2.4 CreaVax

1.2.5 Others

1.3 Market by Application

1.3.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Pediatrics

1.3.3 Adults

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 GLOBAL GROWTH TRENDS

2.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Perspective (2018-2029)

2.2 Dendritic Cell Cancer Vaccine Immunotherapy Growth Trends by Region

2.2.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Dendritic Cell Cancer Vaccine Immunotherapy Historic Market Size by Region (2018-2023)

2.2.3 Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Region (2024-2029)

2.3 Dendritic Cell Cancer Vaccine Immunotherapy Market Dynamics

2.3.1 Dendritic Cell Cancer Vaccine Immunotherapy Industry Trends

2.3.2 Dendritic Cell Cancer Vaccine Immunotherapy Market Drivers

2.3.3 Dendritic Cell Cancer Vaccine Immunotherapy Market Challenges

2.3.4 Dendritic Cell Cancer Vaccine Immunotherapy Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Dendritic Cell Cancer Vaccine Immunotherapy Players by Revenue

3.1.1 Global Top Dendritic Cell Cancer Vaccine Immunotherapy Players by Revenue (2018-2023)

3.1.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Players (2018-2023)

3.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Dendritic Cell Cancer Vaccine Immunotherapy Revenue

3.4 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Concentration Ratio

3.4.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Dendritic Cell Cancer Vaccine Immunotherapy Revenue in 2022

3.5 Dendritic Cell Cancer Vaccine Immunotherapy Key Players Head office and Area Served

3.6 Key Players Dendritic Cell Cancer Vaccine Immunotherapy Product Solution and Service

3.7 Date of Enter into Dendritic Cell Cancer Vaccine Immunotherapy Market

3.8 Mergers & Acquisitions, Expansion Plans

4 DENDRITIC CELL CANCER VACCINE IMMUNOTHERAPY BREAKDOWN DATA BY TYPE

4.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Historic Market Size by Type (2018-2023)

4.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Type (2024-2029)

5 DENDRITIC CELL CANCER VACCINE IMMUNOTHERAPY BREAKDOWN DATA BY APPLICATION

5.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Historic Market Size by Application (2018-2023)

5.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)

6.2 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023)

6.4 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7 EUROPE

7.1 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)

7.2 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023)

7.4 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 ASIA-PACIFIC

8.1 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)

8.2 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2018-2023)

8.4 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2024-2029)

8.5 China

8.6 Japan

- 8.7 South Korea
- 8.8 Southeast Asia
- 8.9 India
- 8.10 Australia

9 LATIN AMERICA

- 9.1 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)
- 9.2 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 9.3 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023)
- 9.4 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029)
- 9.5 Mexico
- 9.6 Brazil

10 MIDDLE EAST & AFRICA

- 10.1 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)
- 10.2 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 10.3 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023)
- 10.4 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029)
- 10.5 Turkey
- 10.6 Saudi Arabia
- 10.7 UAE

11 KEY PLAYERS PROFILES

- 11.1 Lineage Cell Therapeutics
 - 11.1.1 Lineage Cell Therapeutics Company Detail
 - 11.1.2 Lineage Cell Therapeutics Business Overview
 - 11.1.3 Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Introduction

- 11.1.4 Lineage Cell Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
- 11.1.5 Lineage Cell Therapeutics Recent Development
- 11.2 AVAX Technologies
 - 11.2.1 AVAX Technologies Company Detail
 - 11.2.2 AVAX Technologies Business Overview
 - 11.2.3 AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Introduction
 - 11.2.4 AVAX Technologies Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
 - 11.2.5 AVAX Technologies Recent Development
- 11.3 DCPrime
 - 11.3.1 DCPrime Company Detail
 - 11.3.2 DCPrime Business Overview
 - 11.3.3 DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Introduction
 - 11.3.4 DCPrime Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
 - 11.3.5 DCPrime Recent Development
- 11.4 Gradalis
 - 11.4.1 Gradalis Company Detail
 - 11.4.2 Gradalis Business Overview
 - 11.4.3 Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Introduction
 - 11.4.4 Gradalis Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
 - 11.4.5 Gradalis Recent Development
- 11.5 Heat Biologics
 - 11.5.1 Heat Biologics Company Detail
 - 11.5.2 Heat Biologics Business Overview
 - 11.5.3 Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Introduction
 - 11.5.4 Heat Biologics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
 - 11.5.5 Heat Biologics Recent Development
- 11.6 ImmunoCellular Therapeutics
 - 11.6.1 ImmunoCellular Therapeutics Company Detail
 - 11.6.2 ImmunoCellular Therapeutics Business Overview
 - 11.6.3 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Introduction
 - 11.6.4 ImmunoCellular Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)
 - 11.6.5 ImmunoCellular Therapeutics Recent Development

11.7 Immunicum

11.7.1 Immunicum Company Detail

11.7.2 Immunicum Business Overview

11.7.3 Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Introduction

11.7.4 Immunicum Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)

11.7.5 Immunicum Recent Development

11.8 MolecuVax

11.8.1 MolecuVax Company Detail

11.8.2 MolecuVax Business Overview

11.8.3 MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Introduction

11.8.4 MolecuVax Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)

11.8.5 MolecuVax Recent Development

11.9 Northwest Biotherapeutics

11.9.1 Northwest Biotherapeutics Company Detail

11.9.2 Northwest Biotherapeutics Business Overview

11.9.3 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Introduction

11.9.4 Northwest Biotherapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)

11.9.5 Northwest Biotherapeutics Recent Development

11.10 Pique Therapeutics

11.10.1 Pique Therapeutics Company Detail

11.10.2 Pique Therapeutics Business Overview

11.10.3 Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Introduction

11.10.4 Pique Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)

11.10.5 Pique Therapeutics Recent Development

11.11 Regeneus

11.11.1 Regeneus Company Detail

11.11.2 Regeneus Business Overview

11.11.3 Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Introduction

11.11.4 Regeneus Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)

11.11.5 Regeneus Recent Development

11.12 Tessa Therapeutics

11.12.1 Tessa Therapeutics Company Detail

11.12.2 Tessa Therapeutics Business Overview

11.12.3 Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy

Introduction

11.12.4 Tessa Therapeutics Revenue in Dendritic Cell Cancer Vaccine

Immunotherapy Business (2018-2023)

11.12.5 Tessa Therapeutics Recent Development

11.13 Vaccinogen

11.13.1 Vaccinogen Company Detail

11.13.2 Vaccinogen Business Overview

11.13.3 Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Introduction

11.13.4 Vaccinogen Revenue in Dendritic Cell Cancer Vaccine Immunotherapy

Business (2018-2023)

11.13.5 Vaccinogen Recent Development

11.14 XEME Biopharma

11.14.1 XEME Biopharma Company Detail

11.14.2 XEME Biopharma Business Overview

11.14.3 XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Introduction

11.14.4 XEME Biopharma Revenue in Dendritic Cell Cancer Vaccine Immunotherapy

Business (2018-2023)

11.14.5 XEME Biopharma Recent Development

12 ANALYST'S VIEWPOINTS/CONCLUSIONS

13 APPENDIX

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Type (US\$ Million): 2018 VS 2022 VS 2029

Table 2. Key Players of Provenge

Table 3. Key Players of Apceden

Table 4. Key Players of CreaVax

Table 5. Key Players of Others

Table 6. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth by Application (US\$ Million): 2018 VS 2022 VS 2029

Table 7. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 8. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2018-2023) & (US\$ Million)

Table 9. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Region (2018-2023)

Table 10. Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 11. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Region (2024-2029)

Table 12. Dendritic Cell Cancer Vaccine Immunotherapy Market Trends

Table 13. Dendritic Cell Cancer Vaccine Immunotherapy Market Drivers

Table 14. Dendritic Cell Cancer Vaccine Immunotherapy Market Challenges

Table 15. Dendritic Cell Cancer Vaccine Immunotherapy Market Restraints

Table 16. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Players (2018-2023) & (US\$ Million)

Table 17. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Players (2018-2023)

Table 18. Global Top Dendritic Cell Cancer Vaccine Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dendritic Cell Cancer Vaccine Immunotherapy as of 2022)

Table 19. Ranking of Global Top Dendritic Cell Cancer Vaccine Immunotherapy Companies by Revenue (US\$ Million) in 2022

Table 20. Global 5 Largest Players Market Share by Dendritic Cell Cancer Vaccine Immunotherapy Revenue (CR5 and HHI) & (2018-2023)

Table 21. Key Players Headquarters and Area Served

Table 22. Key Players Dendritic Cell Cancer Vaccine Immunotherapy Product Solution

and Service

Table 23. Date of Enter into Dendritic Cell Cancer Vaccine Immunotherapy Market

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2018-2023) & (US\$ Million)

Table 26. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Type (2018-2023)

Table 27. Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 28. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Type (2024-2029)

Table 29. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2018-2023) & (US\$ Million)

Table 30. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Application (2018-2023)

Table 31. Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 32. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Application (2024-2029)

Table 33. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 34. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023) & (US\$ Million)

Table 35. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029) & (US\$ Million)

Table 36. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 37. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023) & (US\$ Million)

Table 38. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029) & (US\$ Million)

Table 39. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 40. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2018-2023) & (US\$ Million)

Table 41. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2024-2029) & (US\$ Million)

Table 42. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

- Table 43. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023) & (US\$ Million)
- Table 44. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029) & (US\$ Million)
- Table 45. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029
- Table 46. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2023) & (US\$ Million)
- Table 47. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2024-2029) & (US\$ Million)
- Table 48. Lineage Cell Therapeutics Company Detail
- Table 49. Lineage Cell Therapeutics Business Overview
- Table 50. Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product
- Table 51. Lineage Cell Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)
- Table 52. Lineage Cell Therapeutics Recent Development
- Table 53. AVAX Technologies Company Detail
- Table 54. AVAX Technologies Business Overview
- Table 55. AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Product
- Table 56. AVAX Technologies Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)
- Table 57. AVAX Technologies Recent Development
- Table 58. DCPrime Company Detail
- Table 59. DCPrime Business Overview
- Table 60. DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Product
- Table 61. DCPrime Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)
- Table 62. DCPrime Recent Development
- Table 63. Gradalis Company Detail
- Table 64. Gradalis Business Overview
- Table 65. Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Product
- Table 66. Gradalis Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)
- Table 67. Gradalis Recent Development
- Table 68. Heat Biologics Company Detail
- Table 69. Heat Biologics Business Overview
- Table 70. Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Product
- Table 71. Heat Biologics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy

Business (2018-2023) & (US\$ Million)

Table 72. Heat Biologics Recent Development

Table 73. ImmunoCellular Therapeutics Company Detail

Table 74. ImmunoCellular Therapeutics Business Overview

Table 75. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product

Table 76. ImmunoCellular Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)

Table 77. ImmunoCellular Therapeutics Recent Development

Table 78. Immunicum Company Detail

Table 79. Immunicum Business Overview

Table 80. Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Product

Table 81. Immunicum Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)

Table 82. Immunicum Recent Development

Table 83. MolecuVax Company Detail

Table 84. MolecuVax Business Overview

Table 85. MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Product

Table 86. MolecuVax Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)

Table 87. MolecuVax Recent Development

Table 88. Northwest Biotherapeutics Company Detail

Table 89. Northwest Biotherapeutics Business Overview

Table 90. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product

Table 91. Northwest Biotherapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)

Table 92. Northwest Biotherapeutics Recent Development

Table 93. Pique Therapeutics Company Detail

Table 94. Pique Therapeutics Business Overview

Table 95. Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product

Table 96. Pique Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)

Table 97. Pique Therapeutics Recent Development

Table 98. Regeneus Company Detail

Table 99. Regeneus Business Overview

Table 100. Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Product

Table 101. Regeneus Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)

Table 102. Regeneus Recent Development

Table 103. Tessa Therapeutics Company Detail

Table 104. Tessa Therapeutics Business Overview

Table 105. Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product

Table 106. Tessa Therapeutics Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)

Table 107. Tessa Therapeutics Recent Development

Table 108. Vaccinogen Company Detail

Table 109. Vaccinogen Business Overview

Table 110. Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Product

Table 111. Vaccinogen Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)

Table 112. Vaccinogen Recent Development

Table 113. XEME Biopharma Company Detail

Table 114. XEME Biopharma Business Overview

Table 115. XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Product

Table 116. XEME Biopharma Revenue in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023) & (US\$ Million)

Table 117. XEME Biopharma Recent Development

Table 118. Research Programs/Design for This Report

Table 119. Key Data Information from Secondary Sources

Table 120. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

- Figure 1. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Comparison by Type (2023-2029) & (US\$ Million)
- Figure 2. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Type: 2022 VS 2029
- Figure 3. Provenge Features
- Figure 4. Apceden Features
- Figure 5. CreaVax Features
- Figure 6. Others Features
- Figure 7. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Comparison by Application (2023-2029) & (US\$ Million)
- Figure 8. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Application: 2022 VS 2029
- Figure 9. Pediatrics Case Studies
- Figure 10. Adults Case Studies
- Figure 11. Dendritic Cell Cancer Vaccine Immunotherapy Report Years Considered
- Figure 12. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size (US\$ Million), Year-over-Year: 2018-2029
- Figure 13. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size, (US\$ Million), 2018 VS 2022 VS 2029
- Figure 14. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Region: 2022 VS 2029
- Figure 15. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Players in 2022
- Figure 16. Global Top Dendritic Cell Cancer Vaccine Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dendritic Cell Cancer Vaccine Immunotherapy as of 2022)
- Figure 17. The Top 10 and 5 Players Market Share by Dendritic Cell Cancer Vaccine Immunotherapy Revenue in 2022
- Figure 18. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 19. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2018-2029)
- Figure 20. United States Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 21. Canada Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY

Growth (2018-2029) & (US\$ Million)

Figure 22. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 23. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2018-2029)

Figure 24. Germany Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 25. France Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 26. U.K. Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 27. Italy Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 28. Russia Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 29. Nordic Countries Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 30. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 31. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Region (2018-2029)

Figure 32. China Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 33. Japan Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 34. South Korea Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 35. Southeast Asia Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 36. India Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 37. Australia Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 38. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 39. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2018-2029)

Figure 40. Mexico Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 41. Brazil Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 42. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 43. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2018-2029)

Figure 44. Turkey Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 45. Saudi Arabia Dendritic Cell Cancer Vaccine Immunotherapy Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 46. Lineage Cell Therapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)

Figure 47. AVAX Technologies Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)

Figure 48. DCPrime Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)

Figure 49. Gradalis Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)

Figure 50. Heat Biologics Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)

Figure 51. ImmunoCellular Therapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)

Figure 52. Immunicum Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)

Figure 53. MolecuVax Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)

Figure 54. Northwest Biotherapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)

Figure 55. Pique Therapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)

Figure 56. Regeneus Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)

Figure 57. Tessa Therapeutics Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)

Figure 58. Vaccinogen Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)

Figure 59. XEME Biopharma Revenue Growth Rate in Dendritic Cell Cancer Vaccine Immunotherapy Business (2018-2023)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

I would like to order

Product name: Global Dendritic Cell Cancer Vaccine Immunotherapy Market Research Report 2023

Product link: <https://marketpublishers.com/r/G5C23C2724E1EN.html>

Price: US\$ 2,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5C23C2724E1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970